Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Elevance Health Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Price to earnings (P/E) 16.06 18.05 19.55 19.80 18.14 17.03 17.46 19.20 18.75 18.07 20.46 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96
Price to operating profit (P/OP) 13.12 14.89 15.42 15.57 14.38 13.36 13.61 15.05 15.30 14.72 17.53 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55
Price to sales (P/S) 0.60 0.71 0.72 0.70 0.66 0.66 0.68 0.74 0.77 0.75 0.89 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74
Price to book value (P/BV) 2.35 2.86 3.01 3.02 2.87 2.86 2.90 3.19 3.24 3.08 3.55 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Elevance Health Inc. P/E ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Elevance Health Inc. P/OP ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Elevance Health Inc. P/S ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Elevance Health Inc. P/BV ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Price to Earnings (P/E)

Elevance Health Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 231,922,815 231,885,874 232,417,867 232,668,735 234,959,135 235,647,808 237,055,805 237,457,776 238,827,582 240,000,694 241,084,780 241,304,369 242,714,676 243,815,480 244,840,654 244,905,689 248,704,310 251,506,458 252,116,097 252,329,919 253,563,697 255,817,204 257,195,705
Selected Financial Data (US$)
Shareholders’ net income (in millions) 1,016 2,300 2,246 856 1,289 1,853 1,989 949 1,618 1,653 1,805 1,137 1,509 1,793 1,665 551 222 2,276 1,523 934 1,183 1,139 1,551
Earnings per share (EPS)2 27.67 28.85 26.87 25.73 25.88 27.20 26.19 25.37 26.01 25.43 25.90 25.30 22.73 17.35 19.25 18.67 19.92 23.52 18.96 19.05 0.00 0.00 0.00
Share price1, 3 444.35 520.93 525.19 509.38 469.31 463.21 457.33 487.13 487.81 459.54 529.84 458.58 424.05 383.59 384.84 296.33 285.80 281.56 280.61 304.06 263.51 288.91 251.00
Valuation Ratio
P/E ratio4 16.06 18.05 19.55 19.80 18.14 17.03 17.46 19.20 18.75 18.07 20.46 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 34.10 33.17 32.73 34.57 31.95 36.16 33.21 26.76 21.95 22.24 25.48 29.13 31.42 33.80 36.79 48.49 58.45 58.36 45.61 41.83
Cigna Group 28.81 25.07 27.03 19.03 17.59 12.80 11.43 13.13 14.99 15.60 15.72 13.43 8.43 8.60 10.62 8.71 14.60 12.08 13.82 13.26
CVS Health Corp. 15.46 9.88 9.66 11.47 10.28 33.58 22.61 27.53 40.34 16.30 16.49 17.39 16.78 14.94 14.44 12.88 10.69 10.20 10.94 14.15
Humana Inc. 23.60 25.45 19.12 17.64 19.98 17.74 20.27 22.52 25.24 19.26 18.48 18.34 22.09 22.82 15.20 14.48 13.49 15.26 19.09 18.10
Intuitive Surgical Inc. 82.75 77.23 65.38 74.11 61.96 79.78 79.43 64.99 56.03 52.74 55.10 59.94 71.86 69.15 89.95 87.47 82.17 70.73 44.27 48.72
Medtronic PLC 26.49 25.70 29.96 30.94 26.88 24.40 22.61 23.38 29.39 30.66 46.71 46.56 55.13 42.80 32.34 26.30 25.38 31.86 32.75 28.78
UnitedHealth Group Inc. 35.85 36.59 30.38 20.53 22.75 22.15 22.01 22.46 26.13 27.70 27.29 26.03 27.92 27.41 23.06 20.54 17.70 16.88 19.91 20.48

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2024 Calculation
EPS = (Shareholders’ net incomeQ3 2024 + Shareholders’ net incomeQ2 2024 + Shareholders’ net incomeQ1 2024 + Shareholders’ net incomeQ4 2023) ÷ No. shares of common stock outstanding
= (1,016,000,000 + 2,300,000,000 + 2,246,000,000 + 856,000,000) ÷ 231,922,815 = 27.67

3 Closing price as at the filing date of Elevance Health Inc. Quarterly or Annual Report.

4 Q3 2024 Calculation
P/E ratio = Share price ÷ EPS
= 444.35 ÷ 27.67 = 16.06

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Elevance Health Inc. P/E ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Price to Operating Profit (P/OP)

Elevance Health Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 231,922,815 231,885,874 232,417,867 232,668,735 234,959,135 235,647,808 237,055,805 237,457,776 238,827,582 240,000,694 241,084,780 241,304,369 242,714,676 243,815,480 244,840,654 244,905,689 248,704,310 251,506,458 252,116,097 252,329,919 253,563,697 255,817,204 257,195,705
Selected Financial Data (US$)
Operating income (in millions) 1,286 2,603 2,900 1,067 1,544 2,407 2,596 1,121 2,045 2,201 2,318 1,053 1,923 1,991 2,081 513 108 3,267 2,111 1,016 1,444 1,348 1,853
Operating profit per share2 33.87 34.99 34.07 32.72 32.64 34.67 33.59 32.36 31.89 31.23 30.22 29.21 26.81 19.25 24.38 24.50 26.14 31.16 23.48 22.43 0.00 0.00 0.00
Share price1, 3 444.35 520.93 525.19 509.38 469.31 463.21 457.33 487.13 487.81 459.54 529.84 458.58 424.05 383.59 384.84 296.33 285.80 281.56 280.61 304.06 263.51 288.91 251.00
Valuation Ratio
P/OP ratio4 13.12 14.89 15.42 15.57 14.38 13.36 13.61 15.05 15.30 14.72 17.53 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 29.37 28.44 28.99 30.54 27.48 30.47 27.70 22.18 18.35 18.63 21.33 24.45 26.84 29.01 31.39 40.69 45.82 45.19 35.87 34.03
Cigna Group 9.41 10.37 11.15 11.51 11.38 10.51 9.34 10.40 12.05 10.20 10.40 9.08 9.12 9.28 11.13 9.03 9.24 7.58 8.59 8.38
CVS Health Corp. 8.14 5.74 5.62 6.96 6.32 15.41 11.67 14.75 20.01 9.97 10.06 10.43 9.43 7.87 7.61 6.65 5.89 5.98 6.19 7.83
Humana Inc. 11.63 13.46 10.79 10.94 13.43 13.47 14.93 16.63 18.96 18.96 17.45 17.08 21.55 14.39 11.02 9.78 9.84 11.28 14.59 15.35
Intuitive Surgical Inc. 89.92 82.80 70.29 75.42 55.63 70.08 66.95 54.49 46.65 44.54 49.98 56.11 67.95 69.51 89.18 88.37 83.88 71.30 43.68 48.89
Medtronic PLC 19.69 18.94 19.27 21.20 19.53 17.99 19.55 20.48 25.40 27.20 38.83 37.44 49.88 42.55 35.86 26.29 21.01 23.52 22.21 21.26
UnitedHealth Group Inc. 15.94 16.11 14.49 14.20 15.63 15.33 15.41 15.89 18.75 19.96 19.69 18.77 19.63 19.05 16.12 14.12 12.35 11.85 13.80 14.40

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2024 Calculation
Operating profit per share = (Operating incomeQ3 2024 + Operating incomeQ2 2024 + Operating incomeQ1 2024 + Operating incomeQ4 2023) ÷ No. shares of common stock outstanding
= (1,286,000,000 + 2,603,000,000 + 2,900,000,000 + 1,067,000,000) ÷ 231,922,815 = 33.87

3 Closing price as at the filing date of Elevance Health Inc. Quarterly or Annual Report.

4 Q3 2024 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 444.35 ÷ 33.87 = 13.12

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Elevance Health Inc. P/OP ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Price to Sales (P/S)

Elevance Health Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 231,922,815 231,885,874 232,417,867 232,668,735 234,959,135 235,647,808 237,055,805 237,457,776 238,827,582 240,000,694 241,084,780 241,304,369 242,714,676 243,815,480 244,840,654 244,905,689 248,704,310 251,506,458 252,116,097 252,329,919 253,563,697 255,817,204 257,195,705
Selected Financial Data (US$)
Operating revenue (in millions) 44,719 43,223 42,273 42,454 42,480 43,377 41,898 39,667 39,625 38,482 37,886 36,018 35,548 33,279 32,098 31,533 30,649 29,178 29,448 27,132 26,444 25,177 24,388
Sales per share2 744.51 734.97 733.95 731.55 712.56 698.36 673.56 655.53 636.49 616.39 592.04 567.51 545.74 523.18 504.24 493.28 468.05 446.12 429.17 408.75 0.00 0.00 0.00
Share price1, 3 444.35 520.93 525.19 509.38 469.31 463.21 457.33 487.13 487.81 459.54 529.84 458.58 424.05 383.59 384.84 296.33 285.80 281.56 280.61 304.06 263.51 288.91 251.00
Valuation Ratio
P/S ratio4 0.60 0.71 0.72 0.70 0.66 0.66 0.68 0.74 0.77 0.75 0.89 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.77 4.53 4.57 4.93 4.13 4.64 4.64 4.25 3.85 4.18 4.42 4.78 5.38 5.36 5.64 6.30 6.13 5.77 5.09 4.83
Cigna Group 0.38 0.43 0.48 0.51 0.49 0.46 0.42 0.49 0.55 0.48 0.48 0.42 0.42 0.42 0.55 0.46 0.50 0.41 0.45 0.44
CVS Health Corp. 0.21 0.20 0.20 0.27 0.26 0.29 0.27 0.36 0.40 0.43 0.44 0.47 0.45 0.39 0.40 0.35 0.32 0.32 0.30 0.37
Humana Inc. 0.28 0.39 0.35 0.42 0.59 0.61 0.66 0.68 0.78 0.68 0.65 0.65 0.73 0.71 0.73 0.64 0.76 0.76 0.74 0.76
Intuitive Surgical Inc. 23.60 21.35 17.76 18.71 13.72 17.06 16.21 13.81 12.62 12.69 15.34 17.89 22.12 21.73 23.19 21.29 20.09 18.44 13.33 15.01
Medtronic PLC 3.44 3.30 3.44 3.72 3.55 3.42 3.79 3.72 4.54 4.54 5.74 5.57 5.71 5.43 5.11 4.36 4.34 4.82 4.72 4.36
UnitedHealth Group Inc. 1.32 1.35 1.24 1.25 1.39 1.35 1.37 1.40 1.62 1.66 1.61 1.58 1.55 1.47 1.49 1.24 1.18 1.17 1.12 1.18

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2024 Calculation
Sales per share = (Operating revenueQ3 2024 + Operating revenueQ2 2024 + Operating revenueQ1 2024 + Operating revenueQ4 2023) ÷ No. shares of common stock outstanding
= (44,719,000,000 + 43,223,000,000 + 42,273,000,000 + 42,454,000,000) ÷ 231,922,815 = 744.51

3 Closing price as at the filing date of Elevance Health Inc. Quarterly or Annual Report.

4 Q3 2024 Calculation
P/S ratio = Share price ÷ Sales per share
= 444.35 ÷ 744.51 = 0.60

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Elevance Health Inc. P/S ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Price to Book Value (P/BV)

Elevance Health Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
No. shares of common stock outstanding1 231,922,815 231,885,874 232,417,867 232,668,735 234,959,135 235,647,808 237,055,805 237,457,776 238,827,582 240,000,694 241,084,780 241,304,369 242,714,676 243,815,480 244,840,654 244,905,689 248,704,310 251,506,458 252,116,097 252,329,919 253,563,697 255,817,204 257,195,705
Selected Financial Data (US$)
Shareholders’ equity (in millions) 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,307 35,991 35,812 35,975 36,060 35,737 34,968 33,853 33,199 33,921 34,455 31,693 31,728 31,332 30,793 29,998
Book value per share (BVPS)2 188.75 181.95 174.72 168.94 163.53 162.13 157.58 152.90 150.70 149.22 149.22 149.44 147.24 143.42 138.27 135.56 136.39 136.99 125.71 125.74 123.57 120.37 116.63
Share price1, 3 444.35 520.93 525.19 509.38 469.31 463.21 457.33 487.13 487.81 459.54 529.84 458.58 424.05 383.59 384.84 296.33 285.80 281.56 280.61 304.06 263.51 288.91 251.00
Valuation Ratio
P/BV ratio4 2.35 2.86 3.01 3.02 2.87 2.86 2.90 3.19 3.24 3.08 3.55 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 4.94 4.69 4.75 5.12 4.40 5.02 5.21 5.06 4.85 5.21 5.56 5.75 6.61 6.38 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49
Cigna Group 2.08 2.25 2.38 2.13 2.04 1.87 1.73 1.95 2.20 1.86 1.84 1.53 1.49 1.44 1.86 1.46 1.61 1.34 1.51 1.49 1.49 1.44 1.42
CVS Health Corp. 1.03 0.95 0.96 1.25 1.19 1.35 1.26 1.61 1.80 1.77 1.79 1.83 1.71 1.47 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25
Humana Inc. 1.83 2.61 2.36 2.70 3.55 3.56 3.81 4.13 4.36 3.91 3.66 3.34 3.63 3.82 3.99 3.55 3.55 3.71 4.04 4.07 3.48 3.38 3.07
Intuitive Surgical Inc. 11.91 10.99 9.31 10.01 7.49 9.57 9.29 7.78 6.71 6.29 7.48 8.59 10.64 10.35 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68
Medtronic PLC 2.15 2.05 2.12 2.26 2.12 2.03 2.23 2.24 2.75 2.77 3.52 3.26 3.14 3.02 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59
UnitedHealth Group Inc. 5.43 5.77 5.38 5.18 5.84 5.68 5.60 5.81 6.80 6.94 6.54 6.27 6.13 5.76 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2024 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= 43,775,000,000 ÷ 231,922,815 = 188.75

3 Closing price as at the filing date of Elevance Health Inc. Quarterly or Annual Report.

4 Q3 2024 Calculation
P/BV ratio = Share price ÷ BVPS
= 444.35 ÷ 188.75 = 2.35

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Elevance Health Inc. P/BV ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.